Pulse Biosciences, Inc. released an updated investor presentation on April 16, 2026, detailing its clinical study on a cardiac catheter for atrial fibrillation and future goals in cardiac technology. This filing underscores ongoing developments in their device technology and clinical aims, reflecting a significant push in the electrophysiology market.